Processa Pharmaceuticals, Inc. (PCSA) has disclosed a new risk, in the Accounting & Financial Operations category.
Processa Pharmaceuticals, Inc. confronts a significant existential threat, highlighted by their latest financial statements which cast substantial doubt on their ability to continue as a going concern. Without any revenue for the year ended December 31, 2023, or prior, and no products or customers to generate future sales, the company’s survival hinges on securing additional financing. This uncertainty, stemming from their ongoing losses and cash flow challenges, could adversely affect their stock price, relationships with partners, and ability to meet debt covenants. Processa’s situation is emblematic of the high risks faced by emerging entities in the pharmaceutical industry.
Overall, Wall Street has a Hold consensus rating on PCSA stock based on 1 Hold.
To learn more about Processa Pharmaceuticals, Inc.’s risk factors, click here.
